| Nov 12 |
Vigil Neuroscience to Present at Upcoming Investor Conferences
|
| Nov 7 |
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 7 |
Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake
|
| Nov 5 |
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
|
| Sep 27 |
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?
|
| Sep 18 |
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial
|
| Sep 17 |
Vigil says FDA removed partial hold on Alzheimer’s candidate
|
| Sep 17 |
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
|
| Aug 13 |
Vigil Neuroscience GAAP EPS of -$0.52
|
| Aug 13 |
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
|
